Stem Cell Sciences (SCS) is an international research and development company specializing in the provision of stem cells and stem cell technologies for research and the clinic SCS takes pride in its long-standing relationships with leading academic centre’s of excellence in the stem cell field, which help maintain the Company’s position at the cutting edge of the stem cell industry. Stem Cell Sciences has an established track record of commercialization with international biotechnology and pharmaceutical companies including Pfizer, Sanofi-Aventis, GSK, Chemicon, Deltagen and Lexicon. Stem Cell Sciences has been active in the stem cell research field since 1994, principally focused on technologies to grow, differentiate, and purify embryonic and neural stem cells. The Company now has a substantial portfolio of patents and patent applications in both adult and embryonic stem cell fields. These include technologies to permit the generation of highly purified stem cells and their differentiated progeny for use in genetic, pharmacological and toxicological screens. Moreover, these technologies can be utilized to provide pure populations of appropriate cell types for transplantation therapies. Stem Cell Sciences’ core objective is to develop safe and effective stem cell-based therapies for currently incurable diseases. We have business and scientific operations in Edinburgh and Cambridge (UK), Melbourne (Australia) and Kobe (Japan). In 2007 SCS will open new offices in California (USA).
The management of generating commerce from these Products & Services is the responsibility of individual business units. These are:
- SC (stem cell) Proven
- SC Services
- SC Licensing
- SC Therapies
Stem Cell Sciences plc
Roger Land Building,
King’s Buildings
West Mains Road
Edinburgh
EH9 3JQ
UNITED KINGDOM
Telephone: +44 (0)131 662 9829
Facsimile: +44 (0)131 662 9779, info@stemcellsciences.com.
Minerva Building 250
Babraham Research Campus
CB22 3AT
Cambridge
UNITED KINGDOM
